Skip to main content
. 2018 Feb 9;19(2):530. doi: 10.3390/ijms19020530

Figure 2.

Figure 2

Biologics targeting the IL-23/IL-17 axis in Psoriasis (Ps) and Psoriatic Arthritis (PsA). Specific monoclonal antibodies targeting IL-23p40, IL-23p19, IL-17A or its receptor IL-17R have been developed and are currently used in clinical practice or still tested inclinical trials (see Table 1).